A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [(177)Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial

SIMPLE SUMMARY: Prostate specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed in prostate cancer cells. For patients with metastatic castration-resistant prostate cancer (mCRPC) who do not respond to conventional treatment, PSMA targeting radiopharmaceutical therapy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Dongho, Ha, Seunggyun, O, Joo Hyun, Rhew, Seung ah, Yoon, Chang Eil, Kwon, Hyeok Jae, Moon, Hyong Woo, Park, Yong Hyun, Park, Sonya Youngju, Park, Chansoo, Chi, Dae Yoon, Yoo, Ie Ryung, Lee, Ji Youl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777064/
https://www.ncbi.nlm.nih.gov/pubmed/36551710
http://dx.doi.org/10.3390/cancers14246225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777064/
https://www.ncbi.nlm.nih.gov/pubmed/36551710
http://dx.doi.org/10.3390/cancers14246225

Ejemplares similares